I lead the Early Oncology R&D team - a global community of over 1000 scientists working to bring the next wave of oncology medicines from target identification and into the clinic. We are investigating new therapies to target treatment-resistant cancers, exploring our medicines in earlier-stage disease and combining high-quality target validation with precision medicine approaches.

Before joining AstraZeneca in March 2022, I was the Director for the Lester and Sue Smith Breast Center at Baylor College of Medicine, USA, where I led an interdisciplinary team of oncologists, pathologists, epidemiologists, basic scientists and statisticians with the shared goal to better understand the molecular profile of breast cancer to improve prevention, diagnosis and treatment. I’m committed to building teams with the diverse competencies necessary for success in oncology research.

My research interests lie in applying precision medicine, multi-omics and medical oncology to discover the next wave of innovative medicines. Some of my research highlights include being the co-lead for The Cancer Genome Atlas Breast Cancer project, deepening our understanding of the proteogenomics of breast cancer through the Clinical Proteomic Tumor Analysis Consortium, and discovering that loss of the NF1 gene is an important driver of breast cancer resistance to hormone therapy. My work is supported by more than 350 publications in peer-reviewed journals including Nature, Cell, Cancer Cell, Cancer Research and Cancer Discovery with almost 70,000 citations and a current h-index of 103.

Throughout my career I’ve been part of several networks and committees, including a member of the National Clinical Trials network, Vice Chair for the NRG Breast Committee and the Cancer and Leukemia Group CALGB Breast Committee (now Alliance), and a member of the FDA’s Oncology Drug Advisory Committee. 


After a lifetime in academic research and medical practice, I’m energised by the potential that the scale of the organisation provides to rapidly deliver new treatments for cancer patients that most need our help.

Matthew Ellis Senior Vice President, Early Oncology, Oncology R&D

2019

Brinker Award for Scientific Distinction in Clinical Research

2015

ASCO Gianni Bonadonna Breast Cancer Award

2015

Stand Up to Cancer Laura Ziskin Prize


CURRENT ROLE

Joined AstraZeneca to lead the Early Oncology R&D team

2020

Work on the NF1 gene published in Cancer Cell provides new insight into breast cancer resistance to hormone therapy

2020

Published research in the journal Cell on the proteogenomic landscape of breast cancer tumorigenesis and targeted therapy

2014 - 2022

Professor and Director of the Sue and Lester Smith Breast Center at Baylor College of Medicine, USA


Featured publications


Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy

Karsten Krug, Eric J Jaehnig, Shankha Satpathy, Lili Blumenberg, Alla Karpova, Meenakshi Anurag, George Miles, Philipp Mertins, Yifat Geffen, Lauren C Tang, David I Heiman, Song Cao, Yosef E Maruvka, Jonathan T Lei, Chen Huang, Ramani B Kothadia, Antonio Colaprico, Chet Birger, Jarey Wang, Yongchao Dou, Bo Wen, Zhiao Shi, Yuxing Liao, Maciej Wiznerowicz, Matthew A Wyczalkowski, Xi Steven Chen, Jacob J Kennedy, Amanda G Paulovich, Mathangi Thiagarajan, Christopher R Kinsinger, Tara Hiltke, Emily S Boja, Mehdi Mesri, Ana I Robles, Henry Rodriguez, Thomas F Westbrook, Li Ding, Gad Getz, Karl R Clauser, David Fenyö, Kelly V Ruggles, Bing Zhang, D R Mani, Steven A Carr, Matthew J Ellis, Michael A Gillette, Clinical Proteomic Tumor Analysis Consortium. Cell. 2020 November 25. 183(5):1436-1456.e31.
Link: https://www.sciencedirect.com/science/article/pii/S0092867420314008?via%3Dihub

Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer

Ze-Yi Zheng, Meenakshi Anurag, Jonathan T. Lei, Jin Cao, Purba Singh, Jianheng Peng, Hilda Kennedy, Nhu-Chau Nguyen, Yue Chen, Philip Lavere, Jing Li, Xin-Hui Du, Burcu Cakar, Wei Song, Beom-Jun Kim, Jiejun Shi, Sinem Seker, Doug W. Chan, Guo-Qiang Zhao, Xi Chen, Kimberly C. Banks, Richard B. Lanman, Maryam Nemati Shafaee, Xiang H.-F. Zhang, Suhas Vasaikar, Bing Zhang, Susan G. Hilsenbeck, Wei Li, Charles E. Foulds, Matthew J. Ellis, Eric C. Chang. Cancer Cell. 20 March 16. Pages 387-402.e7
Lunk: https://www.cell.com/cancer-cell/pdfExtended/S1535-6108(20)30092-1

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer.

Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri & Svasti Haricharan. Nat Commun. 2021 05 19; 12(1):2940. 
Link: https://www.nature.com/articles/s41467-021-23271-0

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.

Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ. Cancer Res. 2021 Dec 15;81(24):6259-6272.
Link: https://aacrjournals.org/cancerres/article/81/24/6259/674841/Transcriptional-Reprogramming-Differentiates

Proteogenomics connects somatic mutations to signalling in breast cancer

Philipp Mertins, D. R. Mani, Kelly V. Ruggles, Michael A. Gillette, Karl R. Clauser, Pei Wang, Xianlong Wang, Jana W. Qiao, Song Cao, Francesca Petralia, Emily Kawaler, Filip Mundt, Karsten Krug, Zhidong Tu, Jonathan T. Lei, Michael L. Gatza, Matthew Wilkerson, Charles M. Perou, Venkata Yellapantula, Kuan-lin Huang, Chenwei Lin, Michael D. McLellan, Ping Yan, Sherri R. Davies, R. Reid Townsend, Steven J. Skates, Jing Wang, Bing Zhang, Christopher R. Kinsinger, Mehdi Mesri, Henry Rodriguez, Li Ding, Amanda G. Paulovich, David Fenyö, Matthew J. Ellis, Steven A. Carr & NCI CPTAC. Nature. 2016 06 02; 534(7605):55-62
Link: https://www.nature.com/articles/nature18003

Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Ron Bose; Shyam M. Kavuri; Adam C. Searleman; Wei Shen; Dong Shen; Daniel C. Koboldt; John Monsey; Nicholas Goel; Adam B. Aronson; Shunqiang Li; Cynthia X. Ma; Li Ding; Elaine R. Mardis; Matthew J. Ellis. Cancer discovery. 2013;3(2):224-37. 2013
Link: https://aacrjournals.org/cancerdiscovery/article/3/2/224/3639/Activating-HER2-Mutations-in-HER2-Gene

Whole-genome analysis informs breast cancer response to aromatase inhibition.

Matthew J. Ellis, Li Ding, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian A. Van Tine, Jeremy Hoog, Reece J. Goiffon, Theodore C. Goldstein, Sam Ng, Li Lin, Robert Crowder, Jacqueline Snider, Karla Ballman, Jason Weber, Ken Chen, Daniel C. Koboldt, Cyriac Kandoth, William S. Schierding, Joshua F. McMichael, Christopher A. Miller, Charles Lu, Christopher C. Harris, Michael D. McLellan, Michael C. Wendl, Katherine DeSchryver, D. Craig Allred, Laura Esserman, Gary Unzeitig, Julie Margenthaler, G. V. Babiera, P. Kelly Marcom, J. M. Guenther, Marilyn Leitch, Kelly Hunt, John Olson, Yu Tao, Christopher A. Maher, Lucinda L. Fulton, Robert S. Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Tammi L. Vickery, Adnan Elhammali, Helen Piwnica-Worms, Sandra McDonald, Mark Watson, David J. Dooling, David Ota, Li-Wei Chang, Ron Bose, Timothy J. Ley, David Piwnica-Worms, Joshua M. Stuart, Richard K. Wilson & Elaine R. Mardis. Nature. 2012;486(7403):353-60
Link: https://www.nature.com/articles/nature11143

Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.

Matthew J. Ellis; Michael Gillette; Steven A. Carr; Amanda G. Paulovich; Richard D. Smith; Karin K. Rodland; R. Reid Townsend; Christopher Kinsinger; Mehdi Mesri; Henry Rodriguez; Daniel C. Liebler. Cancer discovery. 2013; 3 (10): 1108–1112.
Link: https://aacrjournals.org/cancerdiscovery/article/3/10/1108/3455/Connecting-Genomic-Alterations-to-Cancer-Biology

The genomic landscape of breast cancer as a therapeutic roadmap.

Matthew J. Ellis; Charles M. Perou. Cancer discovery. 2013; 3 (1): 27–34.#
Link: https://aacrjournals.org/cancerdiscovery/article/3/1/27/3487/The-Genomic-Landscape-of-Breast-Cancer-as-a

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

Shunqiang Li, Dong Shen, Jieya Shao, Robert Crowder, Wenbin Liu, Aleix Prat, Xiaping He, Shuying Liu, Jeremy Hoog, Charles Lu, Li Ding, Obi L. Griffith, Christopher Miller, Dave Larson, Robert S. Fulton, Michelle Harrison, Tom Mooney, Joshua F. McMichael, Jingqin Luo, Yu Tao, Rodrigo Goncalves, Christopher Schlosberg, Jeffrey F. Hiken, Laila Saied, Cesar Sanchez, Therese Giuntoli, Caroline Bumb, Crystal Cooper, Robert T. Kitchens, Austin Lin, Chanpheng Phommaly, Sherri R. Davies, Jin Zhang, Megha Shyam Kavuri, Donna McEachern, Yi Yu Dong, Cynthia Ma, Timothy Pluard, Michael Naughton, Ron Bose, Rama Suresh, Reida McDowell, Loren Michel, Rebecca Aft, William Gillanders, Katherine DeSchryver, Richard K. Wilson, Shaomeng Wang, Gordon B. Mills, Ana Gonzalez-Angulo, John R. Edwards, Christopher Maher, Charles M. Perou, Elaine R. Mardis, Matthew J. Ellis, Cell reports. 2013;4(6):1116-30.
Link: https://www.sciencedirect.com/science/article/pii/S2211124713004634?via%3Dihub


Veeva ID: Z4-42839
Date of preparation: March 2022